Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Using Pharmacogenomics Testing to Optimize Care in Children with Acute Hematologic Malignancies

Trisha Kissoon, MD MBA

Blood (2019) 134 (Supplement_1): 5062.

https://doi.org/10.1182/blood-2019-129511

Published: 2019

Journal Articles

Genome Data Allow in silico Pharmacogenetic Studies Using the Genetic Makeup of Both the Individual Patient As Well As the Disease

Manja Meggendorfer, PhD, Wencke Walter, PhD, Stephan Hutter, PhD, Constance Baer, PhD, Claudia Haferlach, MD, Wolfgang Kern, MD, Torsten Haferlach, MD

Blood (2019) 134 (Supplement_1): 3360.

https://doi.org/10.1182/blood-2019-126580

Published: 2019

Journal Articles

Pharmacogenomic Prediction of Bleomycin-Induced Pneumonitis in South East Asian Hodgkin Lymphoma Patients

Blood (2018) 132 (Supplement 1): 4111.

https://doi.org/10.1182/blood-2018-99-113952

Published: 2018

Journal Articles

The Clinical Utility of Pharmacogenomics Testing in Assessing Tyrosine Kinase Inhibitor Therapy, Intolerance and Responses in Patients with Chronic Myelogenous Leukemia

Blood (2018) 132 (Supplement 1): 5440.

https://doi.org/10.1182/blood-2018-99-118600

Published: 2018

Journal Articles

Secdrug: A Computational Method for Discovering Novel Secondary Drug Combinations Using Large-Scale Pharmacogenomics Databases

Li Chen, PhD, Ujjal Kumar Mukherjee, PhD, Emily Rankine, Brian G. Van Ness, PhD, Amit Kumar Mitra, PhD

Blood (2018) 132 (Supplement 1): 4473.

https://doi.org/10.1182/blood-2018-99-117653

Published: 2018

Journal Articles

Genetic Characterization of ABT-199 Sensitivity in Human AML

Marie-Eve Bordeleau, PhD, Richard Bisaillon, PhD, Clarisse Thiollier, PhD, Jana Krosl, PhD, Bernhard Lehnertz, PhD, Vincent-Philippe Lavallee, MD, Tara MacRae, Labelle Caroline, Geneviève Boucher, Isabel Boivin, Giovanni D'Angelo, Sylvie Lavallée, Anne Marinier, PhD, Sébastien Lemieux, PhD, Josée Hébert, MD, Guy Sauvageau, MD, PhD

Blood (2018) 132 (Supplement 1): 283.

https://doi.org/10.1182/blood-2018-99-113062

Published: 2018

Journal Articles

Monitoring Voriconazole Pharmacogenomics and Plasma Concentrations in the Treatment and Prevention of Invasive Fungal Disease for Chinese Hematological Patients

XiaoWen Tang, MD, Honglan Qu, Dandan Guo, Ting Xu, Haiping Dai, Zheng Li, Jia Yin, Xiaopeng Tian, Danqing Guo, Yang Xu, MD PhD, Xiaming Zhu, Liyan Miao, Depei Wu, MD

Blood (2017) 130 (Supplement 1): 4827.

https://doi.org/10.1182/blood.V130.Suppl_1.4827.4827

Published: 2017

Journal Articles

Gene-Drug Interactions in AML Patients Identified By RNA Sequencing and Comprehensive Ex Vivo Drug Sensitivity and Resistance Testing

Ashwini Kumar, MRes, Dishaben Rameshbhai Malani, MSc, Bhagwan Yadav, PhD, Matti Kankainen, PhD, Swapnil Potdar, MSc, Mika Kontro, MD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD, Simon Anders, PhD, Caroline A Heckman, PhD

Blood (2017) 130 (Supplement 1): 1398.

https://doi.org/10.1182/blood.V130.Suppl_1.1398.1398

Published: 2017

Journal Articles

Pharmacogenomic Association with Neurotoxicity in Hispanic Children with Acute Lymphoblastic Leukemia (ALL)

Claire A McClain, PharmD, M Brooke Bernhardt, PharmD, MS, Amanda Berger, PharmD, Ryan Winslow, BS, Michael E Scheurer, PhD MPH, Eric S. Schafer, MD MHS

Blood (2016) 128 (22): 3962.

https://doi.org/10.1182/blood.V128.22.3962.3962

Published: 2016

Journal Articles

Pharmacogenomics of Bortezomib in Multiple Myeloma Patients Reveals That the Ubiquitin Ligase SCF-Skp2 Promotes Drug Resistance

James J. Driscoll, MD PhD, Ehsan Malek, MD

Blood (2015) 126 (23): 3021.

https://doi.org/10.1182/blood.V126.23.3021.3021

Published: 2015

Journal Articles

Warfarin pharmacogenomics and African ancestry

Elvin T. Price

Blood (2015) 126 (4): 434–436.

https://doi.org/10.1182/blood-2015-06-649509

Published: 2015

Journal Articles

The intron-22–inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics

Zuben E. Sauna, Jay N. Lozier, Carol K. Kasper, Chen Yanover, Timothy Nichols, Tom E. Howard

Blood (2015) 125 (2): 223–228.

https://doi.org/10.1182/blood-2013-12-530113

Published: 2015

Journal Articles

AML Specific Targeted Drugs Identified By Drug Sensitivity and Resistance Testing: Comparison of Ex Vivo Patient Cells with in Vitro Cell Lines

Disha Malani, MSc, Astrid Murumägi, PhD, Bhagwan Yadav, MSc, Tea Pemovska, MSc, John Patrick Mpindi, MSc, Mika Kontro, MD, Tero Aittokallio, PhD, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Krister Wennerberg, PhD, Maija Wolf, PhD, Olli Kallioniemi, MD PhD

Blood (2014) 124 (21): 2163.

https://doi.org/10.1182/blood.V124.21.2163.2163

Published: 2014

Journal Articles

Pharmacogenomic Study of Carfilzomib in Relapsed/Refractory Multiple Myeloma Suggests That Carfilzomib Is a More Potent Proteasome Inhibitor Than Bortezomib

Qing Zhang, PhD, Christoph Heuck, MD, Ya-Wei Qiang, MD, PhD, Frits van Rhee, MD, PhD, Sarah Waheed, MD, Clyde Bailey, Susan B. Panozzo, Joshua Epstein, DSc, Bart Barlogie, MD, PhD, Saad Z Usmani, MD FACP

Blood (2012) 120 (21): 5015.

https://doi.org/10.1182/blood.V120.21.5015.5015

Published: 2012

Journal Articles

Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia

Blood (2012) 119 (1): 55–63.

https://doi.org/10.1182/blood-2011-08-370825

Published: 2012

Includes: Supplemental data

Journal Articles

Pharmacogenomic Markers of Clinical Efficacy in a Dose-Dense Therapy Regimen (R-CHOP14) in Diffuse Large B Cell Lymphoma

Cristina Napoli, Stefania Nobili, Ida Landini, Gabriele Perrone, Angela Valenti, Marco Brugia, Benedetta Puccini, Gemma Benelli, Morena Doria, Maurizio Martelli, MD, Erica Finolezzi, Alice Di Rocco, Simonetta di Lollo, Luigi Rigacci, Alberto Bosi, Enrico Mini

Blood (2011) 118 (21): 2478.

https://doi.org/10.1182/blood.V118.21.2478.2478

Published: 2011

Journal Articles

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4 , as novel high-risk feature in myeloma treated with Total Therapy 3

John D. Shaughnessy, Jr, Pingping Qu, Saad Usmani, Christoph J. Heuck, Qing Zhang, Yiming Zhou, Erming Tian, Ichiro Hanamura, Frits van Rhee, Elias Anaissie, Joshua Epstein, Bijay Nair, Owen Stephens, Ryan Williams, Sarah Waheed, Yazan Alsayed, John Crowley, Bart Barlogie

Blood (2011) 118 (13): 3512–3524.

https://doi.org/10.1182/blood-2010-12-328252

Published: 2011

Includes: Supplemental data

Journal Articles

Identification of A Pharmacogenomic Profile Associated with High Sensitivity and Low Toxicity to a Combination of Gemtuzumab Ozogamicin Plus Fludarabine, Cytarabine, Idarubicin Regimen In CD33-Positive Acute Myeloid Leukemia (AML) Patients

Blood (2010) 116 (21): 967.

https://doi.org/10.1182/blood.V116.21.967.967

Published: 2010

Journal Articles

Presence of Prior-to-Treatment BCR-ABL Mutations In CD34+CD38- Stem Cells of Newly Diagnosed Chronic Phase CML Patients and Their Correlation with Imatinib Resistance: Implications of Cancer Pharmacogenomics and Pre-Therapeutic Genetic Testing In Personalized Treatment of BCR-ABL+ Leukemia

Zafar Iqbal, BSc, MSc, MPhil, PhD, Mudassar Iqbal, MD, Tanveer Akhtar, MSc, PhD, Mubashar Iqbal Naqvi, BS(CS), Ammara H Tahir, MBBS, Tariq Jameel Gill, MBBS, Muhammad Naeem Abbas, MLT, Abid Jamil, MBBS, PhD, Abid Sohail Taj, MBBS, PhD, Dr Abd-Al-Qayyum, MD, Najeeb ur-Rehman, BS, (Engg), Muhammad Ferhan, MSc, MPhil, Ijaz Hussain Shah, MBBS, FCPS, Muhammad Khalid, MBBS, FCPS, Weng Xian Qin, BSc(MLT), MS, Ahmad Mukhtar Khalid, MSc, PhD, Mahwish Khan, Aamer Aleem, MD, Shahid Mahmood Baig, MPhil, PhD

Blood (2010) 116 (21): 2278.

https://doi.org/10.1182/blood.V116.21.2278.2278

Published: 2010

Journal Articles

Pharmacogenomics-Based Drug Response Prediction Model for Acute Myeloid Leukemia with Normal Karyotype

Dong Hwan (Dennis) Kim, Boram Han, Kyusang Lee, TaeJin Ahn, Dae-soon Son, Insuk Sohn, Sin-Ho Jung, Kyunghee Park, Jun Ho Jang, Kihyun Kim, Hyeoung Joon Kim, MD, PhD, Sang Kyun Sohn, Joon Ho Moon, Jhingook Kim, Nam Huh, Chul Won Jung

Blood (2010) 116 (21): 2698.

https://doi.org/10.1182/blood.V116.21.2698.2698

Published: 2010

NARROW

Using Pharmacogenomics Testing to Optimize Care in Children with Acute Hematologic Malignancies

Genome Data Allow in silico Pharmacogenetic Studies Using the Genetic Makeup of Both the Individual Patient As Well As the Disease

Pharmacogenomic Prediction of Bleomycin-Induced Pneumonitis in South East Asian Hodgkin Lymphoma Patients

The Clinical Utility of Pharmacogenomics Testing in Assessing Tyrosine Kinase Inhibitor Therapy, Intolerance and Responses in Patients with Chronic Myelogenous Leukemia

Secdrug: A Computational Method for Discovering Novel Secondary Drug Combinations Using Large-Scale Pharmacogenomics Databases

Genetic Characterization of ABT-199 Sensitivity in Human AML

Monitoring Voriconazole Pharmacogenomics and Plasma Concentrations in the Treatment and Prevention of Invasive Fungal Disease for Chinese Hematological Patients

Gene-Drug Interactions in AML Patients Identified By RNA Sequencing and Comprehensive Ex Vivo Drug Sensitivity and Resistance Testing

Pharmacogenomic Association with Neurotoxicity in Hispanic Children with Acute Lymphoblastic Leukemia (ALL)

Pharmacogenomics of Bortezomib in Multiple Myeloma Patients Reveals That the Ubiquitin Ligase SCF-Skp2 Promotes Drug Resistance

Warfarin pharmacogenomics and African ancestry

The intron-22–inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics

AML Specific Targeted Drugs Identified By Drug Sensitivity and Resistance Testing: Comparison of Ex Vivo Patient Cells with in Vitro Cell Lines

Pharmacogenomic Study of Carfilzomib in Relapsed/Refractory Multiple Myeloma Suggests That Carfilzomib Is a More Potent Proteasome Inhibitor Than Bortezomib

Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia

Pharmacogenomic Markers of Clinical Efficacy in a Dose-Dense Therapy Regimen (R-CHOP14) in Diffuse Large B Cell Lymphoma

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4 , as novel high-risk feature in myeloma treated with Total Therapy 3

Identification of A Pharmacogenomic Profile Associated with High Sensitivity and Low Toxicity to a Combination of Gemtuzumab Ozogamicin Plus Fludarabine, Cytarabine, Idarubicin Regimen In CD33-Positive Acute Myeloid Leukemia (AML) Patients

Presence of Prior-to-Treatment BCR-ABL Mutations In CD34+CD38- Stem Cells of Newly Diagnosed Chronic Phase CML Patients and Their Correlation with Imatinib Resistance: Implications of Cancer Pharmacogenomics and Pre-Therapeutic Genetic Testing In Personalized Treatment of BCR-ABL+ Leukemia

Pharmacogenomics-Based Drug Response Prediction Model for Acute Myeloid Leukemia with Normal Karyotype

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only